|
|
Article: Palatin Technologies, Inc. Presents Data on Obesity Compounds; Palatin Compounds Effect Decrease in Food Intake & Body Weight in Preclinical Studies.
- Article from:
- Business Wire
- Article date:
- June 14, 2004
|
Copyright informationCOPYRIGHT 2004 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Business Editors/Health/Medical Writers
CRANBURY, N.J.--(BUSINESS WIRE)--June 14, 2004
Palatin Technologies, Inc. (AMEX: PTN) today announced that data on the activity of its lead series of melanocortin receptor, small molecule agonists, under development for the treatment of obesity, were presented at the 8th Annual American Neuroendocrine Society (ANS) Neuroendocrine Workshop. The ANS Workshop, titled "Neuroendocrinology of Energy Balance and Obesity," took place June 13, 2004 at the Hotel Monteleone in New Orleans, LA.
"We are pleased to participate in the American Neuroendocrine Society's annual event," said Carl Spana, Ph.D., president and chief executive ...
Related newspaper, magazine, and journal articles:
|
|
Article: Palatin Technologies Reports Second Quarter Results.
Business Wire;
February 15, 2002 ;
700+ words
......15, 2002 Palatin Technologies, Inc. to...Programs Update Palatin Technologies Inc. (AMEX...31, 2001. Palatin Technologies, February...number-20342664. Palatin Technologies, Inc. is...visit the Palatin web site...facts, are forward-looking ...
|
|